Skip to content
CityAM
Main navigation
  • News
    • News
      • Latest Business News
      • Economics
      • Politics
      • Tech
      • Banking
      • FTSE 100 Live
      • Retail
      • Insurance
      • Legal
      • Property
      • Transport
      • Markets
    • From our partners
      • AON
      • Bayes Business School
      • Canada BIDs
      • Central London Alliance CIC
      • Destination City
      • Halkin
      • Olympia
      • Inside Saudi
      • Tottenham Hotspur Stadium
      • Santander X
      • YEAR SIX Dividend
    • Featured

      PwC UK chief swipes global role in international shake-up

      PwC cuts roles and apprenticeship

      Submit a story

      Tell us your story.

      Submit
  • Opinion
  • Sport
    • Latest Sports News
      • Sport
      • Sport Business
    • From our partners
      • The Morning Briefing: SBS x CityAM
      • Aramco Team Series
      • LIV Golf
    • Featured

      Prem Rugby needs to switch up its calendar to stop final being banished to fringes

      GettyImages 2220159051 showing a significant news event with key figures discussing major topics in a formal setting

      Submit a story

      Tell us your story.

      Submit
  • Life&Style
    • Life&Style
      • Life&Style
      • Toast the City Awards
      • The Magazine
      • Travel
      • Culture
      • Motoring
      • Wellness
      • The RED BULLETiN
      • Do it with Shared Ownership
      • Media Speak Hub
    • Featured

      VW Golf R 2026 long-term review: Final verdict on a classic hot hatch

      Volkswagen Golf parked on a city street showcasing sleek design and modern features in an urban environment

      Submit a story

      Tell us your story.

      Submit
  • Investec
  • Events
  • Latest Paper
Thursday 12 March 2026 3:38 pm  |  Updated:  Friday 13 March 2026 9:53 am

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

By: Business Wire

Add as a preferred source on Google

Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant program is designed to support research conducted by advanced practice nurses (APN), specifically licensed psychiatric-mental health nurse practitioners who are actively engaged in clinical, academic and/or community health center settings and who possess a commitment to advancing treatment of schizophrenia or bipolar I disorder. The application period will run through June 1, 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310230842/en/

“Psychiatric-mental health nurse practitioners bring deep, real‑world insight from the front lines of care,” said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research and Development at Alkermes. “Over the last eight years, Alkermes has demonstrated a strong commitment to supporting early‑career investigators through the Alkermes Pathways Research Awards® program, helping to foster innovative research at pivotal stages in scientific careers. The launch of the Alkermes Pathways APN Research Awards program represents an important evolution of that commitment – expanding our support to advanced practice nurses whose unique perspectives can further inform clinical practice and deepen understanding of serious mental illness, including schizophrenia and bipolar I disorder. We are especially proud to launch this innovative program ahead of this spring’s International Society of Psychiatric Mental Health Nurses and Psych Congress Nurse Practitioner Institute annual meetings.”

“This program creates a meaningful opportunity for nurse practitioners to advance research questions grounded in clinical reality,” said Professor Cynthia Handrup, DNP, Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Illinois Chicago and chair of the Alkermes Pathways APN Research Awards review committee. “I’m honored to work with Alkermes and the review committee to help identify projects with the potential to strengthen evidence and improve patient care.”

The inaugural Alkermes Pathways APN Research Awards program will offer grants in amounts up to $10,000 per project. To qualify, psychiatric-mental health nurse practitioners must be engaged in clinical, academic and/or community health settings and possess a doctoral degree (Ph.D, DNP, etc.) or have a co-investigator or mentor who does. Applications will be formally reviewed by an independent review committee comprised of prominent researchers in the relevant field. For more information on the Alkermes Pathways APN Research Awards program, including full eligibility criteria and how to apply for the inaugural edition of the program, visit http://www.alkermes.com/pathways-apn.

About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Alkermes Pathways APN Research Awards™ is a registered service mark of Alkermes, Inc.
Alkermes Pathways Research Awards® is a registered service mark of Alkermes, Inc. The Alkermes Pathways Research Awards logo is a service mark of Alkermes, Inc.

Alkermes Pathways APN Research Awards announcement with psychiatric nurse practitioners and grant details

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310230842/en/

Contact

Alkermes Contacts:
For Investors: Sandy Coombs, +1 781 609 6377
For Media: Gretchen Murphy, +1 781 609 6419

Company Logo
Company Logo

Company Logo

Company Logo

Read more

Alkermes plc Reports First Quarter 2026 Financial Results

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Photo/Multimedia
  • Product/Service

Trending Articles

  • As it happened: Stocks sink after Fed and Bank of England opt for hawkish hold; Oil price tumbles

  • More Big Four blues as Deloitte plans to slash UK audit roles

  • Baillie Gifford in line for Anthropic windfall just months after £3.6bn SpaceX bonanza

  • City investors raise alarm on Burnham’s Chancellor pick

  • Revolut pays compensation for waking customer up with push notifications

More from CityAM

  • Alkermes plc Reports First Quarter 2026 Financial Results

    Business Wire
  • Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

    Business Wire
  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire
  • Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

    Business Wire
  • Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

    Business Wire
  • Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    Business Wire
  • Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

    Business Wire
  • Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

    Business Wire

CityAM Canada — business, markets and opinion for Canadian readers.

Sections

  • Business
  • Markets
  • Tech
  • AI
  • Economics
  • Opinion
  • Cities

Company

  • About
  • Contact

Legal

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 CityAM Canada. All rights reserved.
Terms · Privacy · Cookies